MOORESTOWN, N.J., Feb. 13, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company providing medication safety solutions for health plans and provider groups, successfully launched, on January 1, 2017, a pilot program to develop and deliver an Enhanced Medication Therapy Management (i.e., Enhanced MTM) program. The pilot involves seven states included in Medicare Part D Region 25: Iowa, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Wyoming. The program addresses the requirements of the Part D Enhanced MTM Model test proposed by the Centers for Medicare and Medicaid Innovation (CMMI), a division of the Centers for Medicare and Medicaid Services (CMS).
Tabula Rasa has deployed its proprietary science and technology Medication Risk Mitigation products and services to perform 360-degree reviews and safety assessments of complex medication regimens, providing an innovative, alternative approach to personalized pharmacotherapy. In this pilot, TRHC has performed medication risk stratification of approximately 240,000 members to identify members at the highest risk for adverse drug events. As a next step, TRHC is collaborating with members who identify as high risk for an adverse drug event, and their prescribers, to further personalize their medication regimens thereby optimizing pharmacotherapy treatment.
“This EMTM partnership is an exciting project – and new market – for us, as we are tasked with optimizing medication use, thus reducing medication-related hospitalizations, and improving coordination of care for tens of thousands of older Americans. This is the first application of our proprietary software outside of the Program for All-inclusive Care of the Elderly (PACE) market, and we believe we can drive similar improvements in outcomes as we do with our PACE partners, including reductions in falls, emergency room visits, and hospitalizations,” said Calvin H. Knowlton, PhD, Chairman and CEO of Tabula Rasa HealthCare. “We believe TRHC’s approach to medication risk mitigation, which is based on the science of individual drug metabolism within a multi-drug regimen, fosters personalization of each medication regimen, which enables better member health outcomes and cost savings. Furthermore, this is a great example of the scalability and flexibility for our Medication Risk Mitigation Software Platform, MedWise Advisor®, as well as our personalized Medication Decision Support processes.”